• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？
Br J Clin Pharmacol. 2018 Jul;84(7):1620-1621. doi: 10.1111/bcp.13538. Epub 2018 Feb 21.
2
Gjestad et al. reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.杰斯塔德等人对纽霍夫和塔克所著的《4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？》一文的回应。
Br J Clin Pharmacol. 2018 Jul;84(7):1624-1625. doi: 10.1111/bcp.13606. Epub 2018 May 10.
3
Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.评价 4β-羟胆固醇和 25-羟胆固醇作为 CYP3A4 内源性生物标志物的研究：用 CYP3A 人源化小鼠进行的研究。
AAPS J. 2018 Apr 9;20(3):61. doi: 10.1208/s12248-018-0186-9.
4
Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.凯珀斯和范霍夫对诺伊霍夫和塔克所著的《4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？》一文作出回应。
Br J Clin Pharmacol. 2018 Jul;84(7):1622-1623. doi: 10.1111/bcp.13592. Epub 2018 Apr 24.
5
4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.4β-羟基胆固醇水平与精神科患者 CYP3A4 底物喹硫平的稳态血清浓度显著相关。
Br J Clin Pharmacol. 2017 Nov;83(11):2398-2405. doi: 10.1111/bcp.13341. Epub 2017 Jul 21.
6
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.4β-羟基胆固醇是一种新的内源性CYP3A标志物：与韩国人、瑞典人和坦桑尼亚人的CYP3A5基因型、奎宁3-羟化作用及性别的关系。
Pharmacogenet Genomics. 2008 Mar;18(3):201-8. doi: 10.1097/FPC.0b013e3282f50ee9.
7
Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time.内源性4β-羟基胆固醇作为评估细胞色素P450 3A（CYP3A）活性生物标志物的效用：尚未完全准备好进入黄金时期。
Eur J Clin Pharmacol. 2022 Nov;78(11):1863-1864. doi: 10.1007/s00228-022-03386-z. Epub 2022 Sep 13.
8
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.4β-羟基胆固醇，一种人体内 CYP3A4/5 活性的内源性标志物。
Br J Clin Pharmacol. 2011 Feb;71(2):183-9. doi: 10.1111/j.1365-2125.2010.03773.x.
9
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.4β-羟基胆固醇作为CYP3A4/5活性的内源性标志物。利福平诱导后消除的稳定性和半衰期。
Br J Clin Pharmacol. 2009 Jan;67(1):38-43. doi: 10.1111/j.1365-2125.2008.03309.x. Epub 2008 Nov 6.
10
Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity.基于一种新方法提高 4β-羟基胆固醇作为 CYP3A4 活性生物标志物测量准确性的临床评估。
Molecules. 2023 Feb 7;28(4):1576. doi: 10.3390/molecules28041576.

引用本文的文献

1
Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism.个体人类细胞色素 P450 酶在药物代谢中的作用。
Pharmacol Rev. 2024 Oct 16;76(6):1104-1132. doi: 10.1124/pharmrev.124.001173.
2
Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.类风湿关节炎患者在持续接受白细胞介素 6 受体拮抗剂治疗期间细胞色素 P450 的活性。
Eur J Clin Pharmacol. 2023 Dec;79(12):1687-1698. doi: 10.1007/s00228-023-03578-1. Epub 2023 Oct 13.
3
Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.探索个体药物代谢特征的新方法，推进精准医学发展。
Drug Metab Dispos. 2023 Oct;51(10):1238-1253. doi: 10.1124/dmd.122.001066. Epub 2023 Jul 7.
4
Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time.内源性4β-羟基胆固醇作为评估细胞色素P450 3A（CYP3A）活性生物标志物的效用：尚未完全准备好进入黄金时期。
Eur J Clin Pharmacol. 2022 Nov;78(11):1863-1864. doi: 10.1007/s00228-022-03386-z. Epub 2022 Sep 13.
5
Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.4β-羟胆固醇与肝和肠道 CYP3A4 的相关性：在广泛体重范围内的患者中的蛋白表达、离体 microsomal 活性和体内活性。
Eur J Clin Pharmacol. 2022 Aug;78(8):1289-1299. doi: 10.1007/s00228-022-03336-9. Epub 2022 Jun 1.
6
A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.一个基于生理学的药代动力学框架，以支持新生儿治疗性低温期间的药物开发和剂量精准度。
Front Pharmacol. 2020 May 13;11:587. doi: 10.3389/fphar.2020.00587. eCollection 2020.
7
Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.利福平与咪达唑仑给药方案指导：用于研究肠道和肝脏细胞色素 P450（CYP）3A4 的诱导和去诱导作用。
AAPS J. 2019 Jun 19;21(5):78. doi: 10.1208/s12248-019-0341-y.
8
Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol-an Interaction Study in Healthy Volunteers.摄入柚子汁对健康志愿者体内内源性 CYP3A4 代谢物 4β-羟基胆固醇血清水平的影响——一项相互作用研究。
AAPS J. 2019 Apr 24;21(4):58. doi: 10.1208/s12248-019-0330-1.
9
Gjestad et al. reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.杰斯塔德等人对纽霍夫和塔克所著的《4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？》一文的回应。
Br J Clin Pharmacol. 2018 Jul;84(7):1624-1625. doi: 10.1111/bcp.13606. Epub 2018 May 10.
10
Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.凯珀斯和范霍夫对诺伊霍夫和塔克所著的《4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？》一文作出回应。
Br J Clin Pharmacol. 2018 Jul;84(7):1622-1623. doi: 10.1111/bcp.13592. Epub 2018 Apr 24.

本文引用的文献

1
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.2018 年 IUPHAR/BPS 药理学指南：更新和扩展，以包含新的免疫药理学指南。
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. doi: 10.1093/nar/gkx1121.
2
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters.2017/18 年药理学简明指南：转运蛋白。
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S360-S446. doi: 10.1111/bph.13883.
3
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.《药理学简明指南 2017/18：酶》
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S272-S359. doi: 10.1111/bph.13877.
4
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors.2017/18 年简明药理学指南：核激素受体。
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S208-S224. doi: 10.1111/bph.13880.
5
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.移植前 4β-羟基胆固醇不能预测肾移植后最初几天他克莫司的暴露或剂量需求。
Br J Clin Pharmacol. 2017 Nov;83(11):2406-2415. doi: 10.1111/bcp.13343. Epub 2017 Jul 14.
6
4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.4β-羟基胆固醇水平与精神科患者 CYP3A4 底物喹硫平的稳态血清浓度显著相关。
Br J Clin Pharmacol. 2017 Nov;83(11):2398-2405. doi: 10.1111/bcp.13341. Epub 2017 Jul 21.
7
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?血浆4β-羟基胆固醇：一种内源性CYP3A指标？
Clin Pharmacol Ther. 2009 Aug;86(2):147-53. doi: 10.1038/clpt.2009.72. Epub 2009 May 20.
8
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.4β-羟基胆固醇作为CYP3A4/5活性的内源性标志物。利福平诱导后消除的稳定性和半衰期。
Br J Clin Pharmacol. 2009 Jan;67(1):38-43. doi: 10.1111/j.1365-2125.2008.03309.x. Epub 2008 Nov 6.
9
PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine.孕烷X受体诱导细胞色素P450 27A1并调节肠道中的胆固醇代谢。
J Lipid Res. 2007 Feb;48(2):373-84. doi: 10.1194/jlr.M600282-JLR200. Epub 2006 Nov 6.
10
Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I.孕烷X受体激动剂可下调肝脏ATP结合盒转运蛋白A1和B1型清道夫受体。
Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.

Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

作者信息

Neuhoff Sibylle, Tucker Geoffrey T

机构信息

Simcyp (Certara) Ltd, Sheffield, UK.

University of Sheffield, Sheffield, UK.

出版信息

Br J Clin Pharmacol. 2018 Jul;84(7):1620-1621. doi: 10.1111/bcp.13538. Epub 2018 Feb 21.

DOI:10.1111/bcp.13538
PMID:29464732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6005580/
Abstract
摘要